Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.

Publication Type:

Journal Article


Blood, Volume 115, Issue 6, p.1288-95 (2010)


2010, Adult, Aged, Aged, 80 and over, Cell Processing Core Facility, Center-Authored Paper, Clinical Research Division, Female, Flow Cytometry Core Facility, Graft Survival, Graft vs Host Disease, Hematologic Neoplasms, hematopoietic stem cell transplantation, Histocompatibility Testing, HLA Antigens, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immunosuppressive Agents, Male, Middle Aged, Prognosis, Research Trials Office Core Facility - Biostatistics Service, Retrospective Studies, Risk Factors, Shared Resources, Siblings, Survival Rate, Tissue Donors, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult


We retrospectively analyzed outcomes among 567 patients with hematologic malignancies who had hematopoietic cell transplantation from human leukocyte antigen-identical sibling donors between 2001 and 2007 for a correlation between statin use and risk of graft-versus-host disease (GVHD). Compared with allografts where neither the donor nor recipient was treated with a statin at the time of transplantation (n = 464), statin use by the donor and not the recipient (n = 75) was associated with a decreased risk of grade 3-4 acute GVHD (multivariate hazard ratio, 0.28; 95% confidence interval, 0.1-0.9). Statin use by both donor and recipient (n = 12) was suggestively associated with a decreased risk of grade 3 or 4 acute GVHD (multivariate hazard ratio, 0.00; 95% confidence interval, undefined), whereas statin use by the recipient and not the donor (n = 16) did not confer GVHD protection. Risks of chronic GVHD, recurrent malignancy, nonrelapse mortality, and overall mortality were not significantly affected by donor or recipient statin exposure. Statin-associated GVHD protection was restricted to recipients with cyclosporine-based postgrafting immunosuppression and was not observed among those given tacrolimus (P = .009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy.